Clinical trial
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Ixazomib Maintenance Study in Patients With AL Amyloidosis
ClinicalTrials.gov ID: NCT03618537
Sponsor: Memorial Sloan Kettering Cancer Center
Information provided by: Memorial Sloan Kettering Cancer Center (Responsible Party)
Last Update Posted: 2023-07-05
Brief Summary:
The purpose of this study is to learn if Ixazomib maintenance treatment (chemotherapy) works to control the disease. Through this study, the investigators hope to learn more about ways to prevent or delay relapse of AL Amyloidosis.
OFFICIAL TITLE
Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
INTERVENTION / TREATMENT
Drug: Ixazomib
Drug: Dexamethasone
| Category | Value |
|---|---|
| Study Start (Actual) | 2018-08-02 |
| Primary Completion (Estimated) | 2026-08 |
| Study Completion (Estimated) | 2026-08 |
| Enrollment (Estimated) | 47 |
| Study Type | Interventional |
| Phase | Phase 2 |
| Other Study ID Numbers |
18-069
|